Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Triamcinolone acetonide suprachoroidal injectable suspension - Clearside Biomedical

Next Previous
X
Search
Drug Profile

Triamcinolone acetonide suprachoroidal injectable suspension - Clearside Biomedical

Alternative Names: Arcatus; ARVN 001; CLS triamcinolone acetonide; CLS-1001; CLS-1003; CLS-1004; CLS-TA; suprachoroidal CLS-TA; triamcinolone acetonide injectable suspension - Bausch Health Companies; Triamcinolone acetonide ophthalmic suspension; XIPERE; ZUPRATA

Latest Information Update: 31 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Clearside Biomedical
  • Developer Arctic Vision; Bausch Health Companies; Clearside Biomedical
  • Class Analgesics; Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienes; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Uveitis
  • Phase II Diabetic macular oedema
  • No development reported Ocular inflammation
  • Discontinued Retinal oedema

Most Recent Events

  • 29 Jul 2024 Preregistration for Uveitis in Singapore (Intraocular) prior to July 2024
  • 29 Jul 2024 Efficacy and adverse events data from a phase III trial in Uveitis released by Arctic vision
  • 30 Nov 2023 Phase-I clinical trials in Diabetic macular oedema in Asia, Australia, India, New Zealand, South Korea (Intraocular) (Clearside Biomedical Pipeline; November 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top